Corcept Therapeutics Incorporated
CORT Healthcare Biotechnology
Corcept Therapeutics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $761.4 million, up 12.8% from fiscal 2024. In the quarter to June 2026, revenue grew 31.7%, EPS grew 21.2% and free cash flow fell 29.9%, each against the same quarter a year earlier. Revenue growth for ten consecutive years; insiders bought in the last twelve months.
Follow CORT
Corcept Therapeutics Incorporated (CORT) P/E ratio
As of 16 October 2026, Corcept Therapeutics Incorporated (CORT) trades at a P/E ratio of 212×. Over the past ten years it has ranged from 0.0× (June 2016) to 458× (September 2016); the current reading is higher than 96% of that period. That is above the Biotechnology industry median of 8.5× and above the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 37.0× | (0.82%) |
| FY2024 | 37.3× | 59.13% |
| FY2023 | 23.5× | 10.48% |
| FY2022 | 21.2× | (6.71%) |
| FY2021 | 22.8× | (19.96%) |
| FY2020 | 28.4× | 95.05% |
| FY2019 | 14.6× | (29.07%) |
| FY2018 | 20.6× | 28.04% |
| FY2017 | 16.1× | (84.78%) |
| FY2016 | 105× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 167× | 86.67% |
| Mar 2026 | 89.6× | 141.96% |
| Dec 2025 | 37.0× | (55.46%) |
| Sep 2025 | 83.1× | 42.67% |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| IBRX ImmunityBio, Inc. compare | n/m |
| MDGL Madrigal Pharmaceuticals, Inc. compare | n/m |
| SMMT Summit Therapeutics PLC compare | n/m |
| BBIO BridgeBio Pharma, Inc. compare | n/m |
| JAZZ Jazz Pharmaceuticals PLC compare | 13.8× |
| HALO Halozyme Therapeutics, Inc. compare | 34.6× |
| TECH Bio-Techne Corp compare | 62.0× |
| BMRN BioMarin Pharmaceutical Inc. compare | 144× |
| CORT Corcept Therapeutics Incorporated | 212× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)